Breaking News From Pharma & Bio Ingredients
NitroMed and Boston Scientific Sign Pact
Posted on 2005-12-29 11:46:00
NitroMed said today that its research program with Boston Scientific, under which NitroMed's nitric oxide-enhancing technology was being studied in connection with restenosis in balloon angioplasty, will conclude on Dec. 31, 2005. NitroMed intends to continue to explore the use of its nitric oxide-enhancing technology in medical devices.
NitroMed of Lexington, MA is a research-based emerging pharmaceutical company and the maker of BiDil (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine that may be prescribed in the U.S. for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as ACE inhibitors and/or beta blockers. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the company's A-HeFT (African American Heart Failure Trial) clinical trial, and is marketed by NitroMed through a nationwide, dedicated sales force.
Subscribe via RSS
